BioMark Receives European Patent for Cancer Diagnostic
Vancouver, British Columbia – (June 18, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the company has been granted a patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE.” The method comprises correlating a presence of the acetylated metabolite of rimantadine or tocainide to spermidine/spermine N1-acetyltransferase […]
BIO STREAM DIAGNOSTICS INC. SELECTED FOR CDL RAPID RESPONSE INNOVATION PROGRAM
Vancouver, British Columbia – (June 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that its affiliated company, Bio Stream Diagnostics Inc., was selected to participate in the global academic science and tech startup program Creative Destruction Lab’s (CDL) recent dedicated Recovery program. CDL Recovery is designed […]
BioMark Diagnostics Inc. Clarifies Prior Disclosure
Vancouver, British Columbia – (June 11 , 2020) – – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, wishes to include additional information to clarify the disclosures in its news release disseminated […]
BioMark Diagnostics Forms New Company, Bio Stream Diagnostics Inc., for ‘30-Second’ COVID-19 Screening
Rapid COVID-19 testing will use machine learning and advanced Raman spectroscopy to provide low-cost, accurate results Vancouver, British Columbia – (June 10 , 2020) – – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and […]
BIOMARK’S LIQUID BIOPSY ASSAY LEVERING METABOLOMICS DEMONSTRATES STRONG PERFORMANCE FOR EARLY LUNG CANCER DETECTION
Vancouver, British Columbia – ( March 24th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection” has been published in the peer-reviewed journal Cancers, validating BioMark’s technology to detect early-stage (I/II) non-small cell lung cancer […]
BioMark Diagnostics Advanced Raman Spectrometer Could Potentially Serve as Complementary Detection Tool for COVID -19 / Coronavirus
Vancouver, British Columbia – (March 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, announced today following their annual technology meeting that their Advanced Raman Spectrometer might have potential to […]
BioMark’s Market Update Report
Vancouver, British Columbia – (February 4th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to provide a market update report with key activities undertaken by BioMark’s team during January 2020. “BioMark is not aware of any negative news that has impacted its share price recently. We continue to execute […]
BIOMARK’S SCIENTIFIC ADVISOR NAMED DEAN OF SCHULICH SCHOOL OF MEDICINE AND DENTISTRY
Vancouver, British Columbia – (January 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) and its team of scientific advisors would like to congratulate Dr. John Yoo for being named Dean of the Schulich School of Medicine & Dentistry on January 6th, 2020. Dr. Yoo has an international reputation as a pioneering […]
BIOMARK DIAGNOSTICS REVIEWS 2019 AND OUTLINES PLANS FOR 2020
Vancouver, British Columbia – (December 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to provide 2019 round up and our outlook for 2020. Below are key highlights. 2019 Round Up 2019 has been a transformative year for BioMark and we anticipate that 2020 would be another […]
BIOMARK CLOSES THE OVER-SUBSCRIBED PRIVATE PLACEMENT OFFERING
Vancouver, British Columbia – (December 16th, 2019) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of November 21st, 2019, it has closed the non-brokered private placement for gross proceeds of $669,347.00 wherein BioMark issued 2,231,157 units at a price […]